ACXP: Acurx Company Aggregate Debts

Symbol and logo of brand acurxpharma.com (ACXP)

The following quotes for the standalone debt of Acurx Pharmaceuticals (ACXP) demonstrate the financial condition of the antibiotic developer, where the indicator stands at 0.00. Stock growth is expected based on the trial results of ibezapolstat and FDA approval. Margin stability is supported by a network of external laboratories, while the current stage is characterized by a lack of sales and the gradual depletion of available cash reserves for scientific research.

Acurx Pharmaceuticals Inc. - ACXP Company Debts (period 07/04/2022 - 10/28/2026)

Analytical breakdowns and data insights for company Acurx Pharmaceuticals (ACXP)

- price and consensus price forecast:
Price Performance Chart acurxpharma.com|ACXP - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Acurx|ACXP - Total Company Value
- book capitalization data:
Accounting Value of a Share Acurx Pharmaceuticals|ACXP - Company Book Value|Market Cap to Net Assets Ratio acurxpharma.com|ACXP - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Acurx Pharmaceuticals|ACXP - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital acurxpharma.com|ACXP - Company Debts|Debt to Book Value Acurx|ACXP - Company Long-Term Debts|Short-Term Debt Volume Acurx Pharmaceuticals
Summary company analytics:ACXP Acurx Pharmaceuticals Inc.
Original product of Acurx Pharmaceuticals, Inc.

This metric aggregates all borrowed fund obligations, neutralizing time lags between quarterly reports to ensure precise monitoring of the debt load. For Acurx Pharmaceuticals (ACXP) within the biotechnology sector, this serves as a critical liquidity marker, as the high scalability of antibiotic development requires significant seed funding, which the total debt structure clearly reflects in the context of future profitability.

Key competitors

Aggregate Debt Obligations Armata (ARMP)